Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 September 2021 | Story Dr Nitha Ramnath
Prof Bonang Mohale.


The executive management of the University of the Free State (UFS) and the university community extend heartfelt congratulations to Prof Bonang Mohale on his appointment as President of Business Unity South Africa (BUSA). 

“Prof Mohale’s extensive expertise and experience in leadership roles, contributions to the growth of many multinational companies, and involvement in education and the business sector, will undoubtedly strengthen the ties between various sectors and civil society, and further contribute to the stabilisation and growth of South Africa,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor, in his congratulatory letter to Prof Mohale. 

BUSA’s role in influencing policy and legislative development for inclusive growth and employment, and in building an enabling environment for the creation of a vibrant, diverse, and globally competitive economy that harnesses the economic and human potential in South Africa, is well documented. This potential resides in our higher education institutions in the form of our students, future graduates, and graduates who are the building blocks for the development of South Africa. 

At a time when our country is facing a social and economic crisis, we are confident that BUSA will consider the perspectives across sectors with a view to creating partnerships, collaboration, and co-creation and further play an integral role in our higher education institutions for the benefit of our students. 

“Prof Mohale’s support to the UFS is appreciated, especially his role as Chancellor and his contribution towards our Thought-Leader and Global Citizen programmes, through which important national and global issues are addressed.
 
We wish Prof Mohale every success in his endeavours, particularly as President of BUSA,” said Prof Petersen.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept